$LLY · Eli Lilly and Company

This Form 4 filing reports a change in beneficial ownership for J. Erik Fyrwald, a director of Eli Lilly and Company. On October 19, 2026, Fyrwald acquired 7.9951 shares of Eli Lilly common stock at a price of $1,240.34 per share. According to the filing, at his election the shares were deferred in lieu of cash compensation as stock units under the Lilly Directors’ Deferral Plan. Those stock units will be settled in shares of common stock after Fyrwald separates from service as a director.

After the reported transaction, Fyrwald directly beneficially owned 75,544.1259 shares of Eli Lilly common stock. The filing was signed and submitted on October 20, 2026, and it reports no other transactions in non-derivative or derivative securities.